Deutsche Bank AG Analysts Give Novartis AG (NOVN) a CHF 81 Price Target

Deutsche Bank AG set a CHF 81 price objective on Novartis AG (VTX:NOVN) in a research report report published on Wednesday. The firm currently has a neutral rating on the stock.

Several other equities research analysts have also recently commented on the stock. Barclays PLC set a CHF 65 target price on shares of Novartis AG and gave the stock a sell rating in a research report on Friday, June 2nd. Jefferies Group LLC set a CHF 103 price target on shares of Novartis AG and gave the company a buy rating in a research report on Friday, June 23rd. Morgan Stanley set a CHF 75 price target on shares of Novartis AG and gave the company a sell rating in a research report on Monday, May 29th. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the company a neutral rating in a research report on Wednesday, June 14th. Finally, HSBC Holdings plc set a CHF 85 price target on shares of Novartis AG and gave the company a buy rating in a research report on Wednesday, June 21st. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of CHF 83.71.

Novartis AG (VTX NOVN) opened at 80.30 on Wednesday. The company has a 50-day moving average of CHK 80.00 and a 200 day moving average of CHK 76.53. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.